CliffBio
small molecule

SYMPAZAN

CLOBAZAM

Loss of exclusivityJanuary 2040latest FDA-listed patent expiry
CompanyASSERTIO SPECIALTY PHARMACEUTICALS LLC

Drug detail

Brand nameSYMPAZAN
Active ingredientCLOBAZAM
Strength20MG
Dosage formFILM
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2018
Marketing statusRX

Listed patents

PatentExpiresType
11541002January 2040product

More from ASSERTIO SPECIALTY PHARMACEUTICALS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SYMPAZAN patent cliff — loss of exclusivity January 2040 | CliffBio